REFLAB ApS: Financial statements 2025
CVR: 15322586
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
REFLAB ApS (CVR 15322586) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 4,582,184 and a net result of DKK -1,792,430 compared with DKK 652,577 the year before. That is a decrease of 22.6% compared with the year before. Equity in the 2025 report amounted to DKK -635,048. The company had 10 employees in the financial year.
- Gross Profit
- DKK 4,582,184
- Profit/Loss
- DKK -1,792,430
- Equity
- DKK -635,048
- Total Assets
- DKK 4,506,262
- Employees
- 10
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 4.6 mio. | -1.8 mio. | -635 t. | 10 |
| 2024 | - | 5.9 mio. | 653 t. | 1.2 mio. | 8 |
| 2023 | - | 3.5 mio. | -936 t. | 505 t. | 7 |
| 2022 | - | 3.2 mio. | -646 t. | 1.4 mio. | 7 |
| 2021 | - | 3.4 mio. | -341 t. | 2.1 mio. | 7 |
Official annual report
How creditworthy is REFLAB ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
REFLAB ApS has published its annual report for 2024. Gross profit came to DKK 5,921,822, and the net result was DKK 652,577.
About REFLAB ApS
REFLAB ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 1991. The company is registered under the industry Traditionelle, komplementære og alternative behandlingsformer. The company was previously named REFERENCELABORATORIET ApS. The management consists of Gert Pynt Andersen and Katrine Baumann Markussen. The company is owned by R-Biopharm AG. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK 4,582,184 and a net result of DKK -1,792,430 compared with DKK 652,577 the year before. Equity in the 2025 report amounted to DKK -635,048.